Consortium partners

The Consortium was established in July 2012 by Merck KGaA, Darmstadt, Germany (Merck KGaA), Astellas Pharma Inc. (Astellas), Swiss Tropical and Public Health Institute (Swiss TPH) and Lygature (formerly TI Pharma). The Consortium operates through an innovative approach that engages new partners as needed:

  • at the beginning of 2014, Farmanguinhos and Simcyp, a Certara company, joined the Consortium as full partners (Simcyp retired in 2017)
  • in the summer of 2016, the Schistosomiasis Control Initiative (SCI), part of Imperial College London, joined 
  • at the beginning of 2018, Kenya Medical Research Institute (KEMRI) and Université Félix Houphouët-Boigny (UFHB) became full partners

Together, the partners bring many different areas of expertise to the project:

Current partners


Merck KGaA (Germany) leads the program. Expert in praziquantel, it provides resources and support from different areas: pre-clinical, clinical, manufacturing, regulatory and access. It is responsible for the clinical development program and is the sponsor of the clinical trials.

 


Astellas Pharma Inc. (Japan) has developed the new pediatric PZQ formulations, and provides expert advice on clinical development in children, and pharmacokinetic modeling.

 


Swiss Tropical and Public Health Institute (Switzerland) is a not-for-profit Institute internationally renowned for its research, services, teaching and training in global health. It contributes with extensive experience in helminths biological and pharmacological research; epidemiology; and clinical research in endemic regions.


Lygature (The Netherlands), a not-for-profit foundation, acts as the independent coordinator of the Consortium, providing governance in terms of progress, finance and collaboration. Since 2006, Lygature has supported close to a hundred public-private partnerships in the field of life sciences & health, including poverty-related diseases.


Farmanguinhos (Brazil), the federal governmental pharmaceutical laboratory of the Fiocruz Foundation in Brazil, brings unique expertise to addressing the production and distribution of new pediatric formulations in endemic countries.

 


The Schistosomiasis Control Initiative (United Kingdom)​ at Imperial College London, is a non-profit initiative that supports treatment programs against schistosomiasis and soil-transmitted helminthiasis in sub-Saharan African countries and Yemen. It will facilitate preparation and implementation of the Access and Delivery plan.


Kenya Medical Research Institute (Kenya), provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the conduct of the trials in Kenya according to Good Clinical Practice and national and local regulatory and ethics standards.

 


Université Félix Houphouët-Boigny (Côte d’Ivoire) was previously involved in the phase II clinical trials of the pediatric praziquantel formulation. It provides expertise on local disease epidemiology, clinical trials and clinical care and will be responsible for the phase III trials in Côte d’Ivoire according to Good Clinical Practice and national and local regulatory and ethics standards.


 

Retired partners